0.10Open0.10Pre Close0 Volume64 Open Interest3.00Strike Price0.00Turnover0.00%IV275.76%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma8.25Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Acurx Pharmaceuticals Stock Discussion
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications
Acurx Pharmaceuticals has provided updates on the Phase 3 readiness of its lead antibiotic candidate, ibezapolstat, for treating C. difficile Infection (CDI). The FDA has given positive feedback on the proposed Chemistry Manufacturing and Controls (CMC) plan, and Acurx is awaiting final advice from the European Medicines Agency (EMA) for the P...
💰 BTC ETFs : $774.6M 📈
💰 ETH ETFs : -$30M 📉
⚡Elon Musk and Vivek Ramaswamy to launch "Dogecast" podcast for the #DOGE Department of Government Efficiency.
💰 BlackRock and Fidelity's spot #Bitcoin ETFs did a combined $4.17 BILLION in trading volume today
🔥 Biopharmaceutical company Acurx Pharmaceuticals is buying up to $1 million in #Bitcoin💰 as a treasury reserve asset
⚡️Bitwise registers for its #Solana💰 ETF in Delaware, per state d...
Acurx Announces Additional Ibezapolstat Ph2b Results in CDI as well as Anthrax (B. anthracis) Susceptibility to ACX-375 Analogues
Acurx Pharmaceuticals (NASDAQ: ACXP)announced new analyses extending data on ibezapolstat's beneficial effects on the gut microbiome for C. difficile Infection (CDI) treatment. The data showed increased beneficial bacteria, reversing dysbiosis and contributing to CDI anti-recurrence. Ibezapolstat's favorable pharmacokinetics were c...
Acurx Announces Additional Ibezapolstat Ph2B Results in Cdi as Well as Anthrax (B. Anthracis) Susceptibility to Acx-375 Analogues
Acurx Announces Results of Its Pioneering Research with Ibezapolstat in Collaboration with Leiden University Medical Center at the Premier International C. difficile Symposium
Acurx Pharmaceuticals (NASDAQ: ACXP) announced results from its research on ibezapolstat in collaboration with Leiden University Medical Center (LUMC) at the International C. difficile Symposium. The research revealed high-resolution details of ibezapolstat's interaction with its mole...
oIn September 2024, the World Antimicrobial Resistance conference in Philadelphia;oIn September 2024,...
No comment yet